



# **Methotrexate**

Catalog No: tcsc1732

#### **Available Sizes**

Size: 100mg

Size: 500mg



### **Specifications**

**CAS No:** 

59-05-2

Formula:

 $C_{20}H_{22}N_8O_5$ 

### **Pathway:**

Cell Cycle/DNA Damage; Antibody-drug Conjugate/ADC Related

**Target:** 

Antifolate; ADC Cytotoxin

**Purity / Grade:** 

>98%

**Solubility:** 

DMSO :  $\geq$  30 mg/mL (66.02 mM)

**Alternative Names:** 

Amethopterin; CL14377; WR19039

**Observed Molecular Weight:** 

454.44

## **Product Description**

Methotrexate is a traditional **folate** antagonist, with median  $IC_{50}$  of 78 nM for a 120 h drug exposure in a panel of six pediatric leukemia and lymphoma cell lines using the sulforhodamine B assay.





IC50 & Target: Antifolate<sup>[1]</sup>

*In Vitro:* Methotrexate (MTX), which has a more predictable toxicity profile than aminopterin, has become a cornerstone of the treatment for childhood acute lymphoblastic leukemia (ALL) and for non-Hodgkins lymphoma<sup>[1]</sup>.

In Vivo: Methotrexate (MTX) exposure reduces thymus and spleen indices of mice. Methotrexate markedly decreases white blood cells, thymic and splenic lymphocytes at dose  $\geq 5$  mg/kg. However, there is a significant difference between the treatment plus control group and the model group (p[2].

$$\begin{array}{c} NH_2 \\ N \end{array}$$

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!